A number of other research firms also recently issued reports on CLIN. N+1 Singer reissued a buy rating and set a GBX 800 ($9.75) price target on shares of Clinigen Group PLC in a research report on Wednesday, September 28th. Stifel Nicolaus reaffirmed a buy rating and issued a GBX 800 ($9.75) target price on shares of Clinigen Group PLC in a research report on Wednesday, July 20th. Finally, Numis Securities Ltd reaffirmed a buy rating and issued a GBX 916 ($11.16) target price on shares of Clinigen Group PLC in a research report on Wednesday, July 20th. Five investment analysts have rated the stock with a buy rating, Clinigen Group PLC has an average rating of Buy and a consensus price target of GBX 856.60 ($10.44).
Clinigen Group PLC (LON:CLIN) opened at 772.50 on Tuesday. Clinigen Group PLC has a 1-year low of GBX 492.75 and a 1-year high of GBX 793.50. The company’s 50-day moving average price is GBX 695.99 and its 200-day moving average price is GBX 612.87. The stock’s market cap is GBX 885.28 million.
The firm also recently declared a dividend, which will be paid on Friday, November 25th. Investors of record on Thursday, November 3rd will be paid a GBX 2.70 ($0.03) dividend. This is a boost from Clinigen Group PLC’s previous dividend of $1.30. The ex-dividend date of this dividend is Thursday, November 3rd. This represents a dividend yield of 0.38%.
In related news, insider Shaun Edward Chilton sold 97,246 shares of the business’s stock in a transaction dated Tuesday, October 18th. The stock was sold at an average price of GBX 750 ($9.14), for a total value of £729,345 ($888,903.11).
Clinigen Group PLC Company Profile
Clinigen Group plc is a United Kingdom-based global pharmaceutical and services company. The Company consists of four businesses that provide medicines to patients with unmet needs, through clinical trials, licensed and unlicensed supply. It operates through four segments: Clinigen Clinical Trial Services (CTS), Idis Managed Access (MA), Idis Global Access (GA) and Clinigen Specialty Pharmaceuticals (SP).
Receive News & Ratings for Clinigen Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group PLC and related companies with MarketBeat.com's FREE daily email newsletter.